Intraperitoneal therapy for ovarian cancer: A treatment ready for prime time

Journal of Clinical Oncology

Volumn 24, Issue 28, 2006, Pages 4531-4533

  Armstrong, Deborah K ^a   Brady, Mark F ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Buffalo Niagara Enterprise   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; HUMAN; NOTE; OVARY CANCER; PRIORITY JOURNAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; OVARY TUMOR; STANDARD; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 33750582548     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.7140     Document Type: Note

References (13)

1. Gore M, du Bois A, Vergote I: Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24:4528-4530, 2006
2. Armstrong D, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
3. Brady MF: First-line therapy in ovarian cancer: Surrogate endpoints for accelerated approval. FDA Ovarian Cancer Endpoints Workshop, Bethesda, MD, April 26, 2006. http://www.fda.gov/cder/drug/cancer_endpoints/#ovarian
4. Eisenhauer E: Clinical trial endpoints for regulatory approval: First-line therapy for advanced ovarian cancer. FDA Ovarian Cancer Endpoints Workshop, Bethesda, MD, April 26, 2006. http://www.fda.gov/cder/drug/ cancer_endpoints/#ovarian
5. du Bois, Quinn M, Thigpen T, et al: 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16:viii7-viii12, 2005 (suppl 8)
6. Vermorken JB, Parmar MKB, Brady MF, et al: Clinical trials in ovarian carcinoma: Study methodology. Ann Oncol 16:viii20-viii29, 2005 (suppl 8)
7. National Cancer Institute: Clinical Announcement: Intraperitoneal chemo-therapy for ovarian cancer, January 5, 2006. http://www.cancer.gov/ newscenter/pressreleases/IPchemotherapyrelease
8. Jaaback K, Johnson N: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer [Cochrane Database Review]. Oxford, United Kingdom, Cochrane Library, Issue 1, CD005340.pub2,2006 (DOI: 10.1002/14651858.CD005340.pub2)
9. Ozols RF, Bookman MA, Young RC: Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med 354:1641-1643, 2006
10. Piccart MJ, Bertelsen K, Stuart G, et al: Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13:144-148, 2003 (suppl 2)
11. Theory and Practice of Clinical Trials (section 5, chapter 24), in Bast RC Jr, Kufe DW, Pollock RE, et al (eds): Cancer Medicine (ed 6). Hamilton, Canada, BC Decker Inc, 2003
12. Wenzel LB, Huang HQ, Armstrong DK, et al: Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 24:257s, 2006 (suppl; abstr 5007)
13. Cannistra SA: Intraperitoneal chemotherapy comes of age. N Engl J Med 354:77-79, 2006